[Clinical evaluation of the use of teicoplanin for staphylococcal infections in immunocompetent and immunodepressed patients].
The authors have evaluated the efficacy and tolerance of teicoplanin against Gram-positive infections in 8 patients (four with endocarditis, one with cholangitis, one with purulent arthritis, one with gathered fistula and one with general pyoderma), arose both in the immunocompetent and immunodepressed subjects. All patients received IM teicoplanin at a dosage of 200-400 mg/die, according to the severity of the infectious process. Teicoplanin proved to be an effective and well-tolerated drug in the treatment of staphylococcus infections, both for immunocompetent and with serious deficit of the immune system subjects.
Catania
S
S
Istituto Malattie Infettive, Università La Sapienza, Roma.
Trinchieri
V
V
Lanzalone
C M
CM
Causo
T
T
Allegra
C
C
Catania
N
N
Cirelli
A
A
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000276:immunology; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D017334:Teicoplanin
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin
Valutazione clinica dell'impiego della teicoplanina nelle infezioni stafilococciche in soggetti immunocompetenti ed immunodepressi.